Mablink presents at the digital 9th Antibody Industrial Symposium (June 22-25, 2021) Our Chief Scientific Officer, Dr Warren Viricel, is giving a presentation at the 9th virtual Antibody Industrial Symposium …
Mablink Bioscience to move forward its ADC pipeline targeted at cancers with high unmet medical needs Lyon, France, April 27, 2021 Mablink Bioscience, a company developing the next generation of …
Mablink’s R&D team authored a scientific article published today (March 9) in the journal “Pharmaceuticals”. The paper “Exatecan Antibody Drug Conjugates based on a hydrophilic polysarcosine Drug-Linker platform” characterizes a …
Le quotidien “Le Figaro” s’est fait l’écho de l’engouement de l’industrie pharmaceutique pour l’approche ADC (anticorps conjugués) dans un article publié le 3 mars : lien vers l’article. Mablink est …
Dr. Warren Viricel, our company’s Chief Scientific Officer, is invited to present Mablink’s PSARlink™ drug-linker technology at the 12th annual PEGS Europe Virtual summit (Lisbon, PT) on Tuesday, November 10, …
Mablink’s Chief Scientific Officer Warren Viricel presents preclinical data of our drug-linker ADC platform based on the topoisomerase I inhibitor Exatecan vs. HER-2 ADC gold standard Enhertu® in a mouse …
On October 14, during the MATWIN board meeting, Mablink’s COO Valérie Attuil was pitching in front of a panel of investors as part of the 2nd Oncology Upward Investment event. …
Mablink will present preclinical data of our drug-linker ADC platform based on a topoisomerase I inhibitor vs. gold standard Enhertu in a mouse model of gastric cancer.
We would like to thank Agatha Inc. very much for their kind post and their support in Mablink’s structuration. Agatha’s solution has brought us a significant move toward putting in …
We are pleased to announce a strategic addition to Mablink’s team with the arrival of Edouard Leroy as our Chief Business Development Officer.
